Loading cancer entity…
Loading cancer entity…
Clinical trials
8,119 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,289)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00115700 | Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma | completed | Phase 3 | 150 | Trans Tasman Radiation Oncology GroupOTHER | 3 | Nov 18, 2022 | clinicaltrials |
| NCT01568866 | Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients(ENDEAVOR) | completed | Phase 3 | 929 | AmgenINDUSTRY | 27 | Nov 14, 2022 |
| NCT01345019 | Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma | completed | Phase 3 | 1,718 | AmgenINDUSTRY | 29 | Nov 8, 2022 | clinicaltrials |
| NCT01335399 | Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma(ELOQUENT - 1) | completed | Phase 3 | 748 | Bristol-Myers SquibbINDUSTRY | 20 | Sep 30, 2022 | clinicaltrials |
| NCT02412878 | Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma(ARROW) | completed | Phase 3 | 478 | AmgenINDUSTRY | 20 | Sep 23, 2022 | clinicaltrials |
| NCT01080391 | Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma | completed | Phase 3 | 792 | AmgenINDUSTRY | 20 | Sep 21, 2022 | clinicaltrials |
| NCT02747043 | Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab(JASMINE) | completed | Phase 3 | 256 | AmgenINDUSTRY | 20 | Sep 10, 2022 | clinicaltrials |
| NCT02063685 | Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma | completed | Phase 3 | 807 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT01239797 | Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma(ELOQUENT - 2) | completed | Phase 3 | 646 | Bristol-Myers SquibbINDUSTRY | 23 | Jun 1, 2022 | clinicaltrials |
| NCT03029234 | Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma | completed | Phase 3 | 126 | AmgenINDUSTRY | 1 | May 25, 2022 | clinicaltrials |
| NCT02197221 | Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma(IFM2014-02) | completed | Phase 3 | 300 | University Hospital, ToulouseOTHER | 2 | May 23, 2022 | clinicaltrials |
| NCT02787239 | Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL | completed | Phase 3 | 407 | Shanghai Henlius BiotechINDUSTRY | 1 | May 9, 2022 | clinicaltrials |
| NCT02566395 | Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies | completed | Phase 3 | 10 | Northwell HealthOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT01078454 | Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis | completed | Phase 3 | 11 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2022 | clinicaltrials |
| NCT01712789 | Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma(STRATUS) | completed | Phase 3 | 682 | CelgeneINDUSTRY | 20 | Jan 10, 2022 | clinicaltrials |
| NCT01109004 | Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) | completed | Phase 3 | 758 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Dec 9, 2021 | clinicaltrials |
| NCT01597778 | Double Cord Versus Haploidentical (BMT CTN 1101) | completed | Phase 3 | 368 | Medical College of WisconsinOTHER | 1 | Dec 1, 2021 | clinicaltrials |
| NCT01777152 | ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas(ECHELON-2) | completed | Phase 3 | 452 | Seagen Inc.INDUSTRY | 16 | Nov 30, 2021 | clinicaltrials |
| NCT00177047 | Autologous Transplant for Multiple Myeloma | completed | Phase 2 / Phase 3 | 363 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 9, 2021 | clinicaltrials |
| NCT00000658 | A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma | completed | Phase 3 | 250 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 3, 2021 | clinicaltrials |
| NCT00075829 | Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) | completed | Phase 3 | 710 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Nov 1, 2021 | clinicaltrials |
| NCT00329030 | Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) | completed | Phase 3 | 224 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Nov 1, 2021 | clinicaltrials |
| NCT02495922 | A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma(GMMG-HD6) | completed | Phase 3 | 564 | University of Heidelberg Medical CenterOTHER | 1 | Sep 10, 2021 | clinicaltrials |
| NCT01122472 | Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP(REMARC) | completed | Phase 3 | 650 | The Lymphoma Academic Research OrganisationOTHER | 9 | Jul 26, 2021 | clinicaltrials |
| NCT01419665 | GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)(ASSIST_FL) | completed | Phase 3 | 629 | SandozINDUSTRY | 26 | May 14, 2021 | clinicaltrials |
| NCT00773747 | Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) | completed | Phase 3 | 637 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 30, 2021 | clinicaltrials |
| NCT02112175 | Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM(ARUMM) | completed | Phase 3 | 46 | CelgeneINDUSTRY | 5 | Apr 14, 2021 | clinicaltrials |
| NCT02128061 | Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+ | completed | Phase 3 | 250 | The Lymphoma Academic Research OrganisationOTHER | 2 | Apr 13, 2021 | clinicaltrials |
| NCT02260804 | To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma | completed | Phase 3 | 258 | CelltrionINDUSTRY | 1 | Apr 8, 2021 | clinicaltrials |
| NCT02165397 | Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia | completed | Phase 3 | 181 | Pharmacyclics LLC.INDUSTRY | 9 | Mar 3, 2021 | clinicaltrials |
| NCT02910063 | Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL | completed | Phase 2 / Phase 3 | 41 | AmgenINDUSTRY | 8 | Jan 13, 2021 | clinicaltrials |
| NCT01578499 | A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)(ALCANZA) | completed | Phase 3 | 131 | Millennium Pharmaceuticals, Inc.INDUSTRY | 12 | Jan 5, 2021 | clinicaltrials |
| NCT01102426 | Aplidin - Dexamethasone in Relapsed/Refractory Myeloma(ADMYRE) | completed | Phase 3 | 255 | PharmaMarINDUSTRY | 19 | Nov 10, 2020 | clinicaltrials |
| NCT02809053 | A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma(RAMO-2) | completed | Phase 3 | 315 | Archigen Biotech LimitedINDUSTRY | 14 | Oct 8, 2020 | clinicaltrials |
| NCT03242902 | To Decrease Fatigue With Light Therapy(SPARKLE) | completed | Phase 3 | 166 | The Netherlands Cancer InstituteOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT00491491 | Zevalin-beam for Aggressive Lymphoma | completed | Phase 3 | 60 | Sheba Medical CenterOTHER_GOV | 4 | Aug 31, 2020 | clinicaltrials |
| NCT02867566 | A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients | completed | Phase 3 | 420 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Aug 12, 2020 | clinicaltrials |
| NCT01285765 | Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients | completed | Phase 3 | 650 | The Lymphoma Academic Research OrganisationOTHER | 2 | Jul 14, 2020 | clinicaltrials |
| NCT01854567 | P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies | completed | Phase 3 | 49 | Mesoblast, Ltd.INDUSTRY | 1 | Jun 26, 2020 | clinicaltrials |
| NCT02322320 | Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT) | completed | Phase 3 | 273 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | May 11, 2020 | clinicaltrials |
| NCT01413178 | A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma | completed | Phase 3 | 205 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 21, 2020 | clinicaltrials |
| NCT01829711 | Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia | completed | Phase 3 | 80 | MedImmune LLCINDUSTRY | 14 | Apr 8, 2020 | clinicaltrials |
| NCT01023308 | Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma(PANORAMA-1) | completed | Phase 3 | 767 | Novartis PharmaceuticalsINDUSTRY | 34 | Mar 17, 2020 | clinicaltrials |
| NCT01611090 | A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 3 | 578 | Janssen Research & Development, LLCINDUSTRY | 21 | Mar 3, 2020 | clinicaltrials |
| NCT00088530 | BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) | completed | Phase 3 | 140 | CTI BioPharmaINDUSTRY | 20 | Feb 5, 2020 | clinicaltrials |
| NCT02162771 | To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan(rituximab) | completed | Phase 3 | 140 | CelltrionINDUSTRY | 0 | Jan 29, 2020 | clinicaltrials |
| NCT01059630 | A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN) | completed | Phase 3 | 413 | Genentech, Inc.INDUSTRY | 14 | Jan 13, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Nov 18, 2022source: clinicaltrials